You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePotassium Citrate
Accession NumberDB09125
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionPotassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. Potassium Citrate is indicated also for the management of Hypocitraturic calcium oxalate nephrolithiasis.
Structure
Thumb
Synonyms
tripotassium citrate
External IDs Not Available
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium CitrateTablet15 meq/1OralBiocomp Pharma, Inc.2013-12-23Not applicableUs
Potassium CitrateTablet5 meq/1OralUpsher Smith Laboratories2006-09-01Not applicableUs
Potassium CitrateTablet10 meq/1OralUpsher Smith Laboratories2006-09-01Not applicableUs
Urocit KTablet, extended release540 mgOralMission Pharmacal1995-01-01Not applicableCanada
Urocit-KTablet, extended release10 meq/1OralMission Pharmacal1992-09-01Not applicableUs
Urocit-KTablet, extended release10 meq/1OralPhysicians Total Care, Inc.2003-04-17Not applicableUs
Urocit-KTablet, extended release15 meq/1OralMission Pharmacal2010-01-27Not applicableUs
Urocit-KTablet, extended release15 meq/1OralPhysicians Total Care, Inc.2010-09-15Not applicableUs
Urocit-KTablet, extended release10 meq/1OralRemedy Repack2016-12-27Not applicableUs
Urocit-KTablet, extended release1080 mgOralMission Pharmacal2011-02-11Not applicableCanada
Urocit-KTablet, extended release5 meq/1OralMission Pharmacal1985-09-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Potassium CitrateTablet, extended release10 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Potassium CitrateTablet, extended release15 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Potassium CitrateTablet, extended release10 meq/1OralAmerincan Health Packaging2014-10-01Not applicableUs
Potassium CitrateTablet, extended release5 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Potassium CitrateTablet, extended release1080 mg/1OralPhysicians Total Care, Inc.2006-07-24Not applicableUs
Potassium CitrateTablet, extended release10 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Potassium CitrateTablet, extended release5 meq/1OralCadila Pharnmaceuticals2014-08-12Not applicableUs
Potassium CitrateTablet, extended release15 meq/1OralZydus Pharmaceuticals Usa, Inc.2014-08-12Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
B6 Plus TabVita Health Products Inc
Cytra-K CrystalsCypress Pharmaceuticals, Inc.
Formula No. 2 Plus K LiqGolden Pride/Rawleigh
Lytren Rhs LiqMead Johnson Nutritionals
Potassium Citrate and Citric AcidPharmaceutical Associates, Inc.
Potassium Citrate Citric Acid CrystalsVirtus Pharmaceuticals
Potassium Citrate-citric AcidMethod Pharmaceuticals
Potassium Citrate-sodium Citrate-citric AcidMethod Pharmaceuticals
TricitratesPharmaceutical Associates, Inc.
Categories
UNII86R1NVR0HW
CAS numberNot Available
WeightAverage: 306.394
Monoisotopic: 305.89464697
Chemical FormulaC6H5K3O7
InChI KeyQEEAPRPFLLJWCF-UHFFFAOYSA-K
InChI
InChI=1S/C6H8O7.3K/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
IUPAC Name
tripotassium 2-hydroxypropane-1,2,3-tricarboxylate
SMILES
[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
Pharmacology
IndicationFor the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.
Structured Indications
PharmacodynamicsPotassium citrate induces changes in the urine which renders urine less susceptible to the formation of crystals and stones from salts e.g. calcium oxalate, calcium phosphate and uric acid. Increased citrate levels in the urine will make complexation with calcium which decrease the calcium ion activity and decrease the chance for the formation of calcium phosphate crystals. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate.
Mechanism of actionAfter oral administration of potassium citrate, its metabolism yields alkaline load. Potassium Citrate therapy appears to increase urinary citrate mainly by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. In addition to raising urinary pH and citrate, Potassium Citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, Potassium Citrate causes a transient reduction in urinary calcium.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Potassium Citrate is absorbed and the citrate is metabolised to bicarbonate.

Route of eliminationUrinary; less than 5% unchanged.
Half lifeNot Available
ClearanceNot Available
Toxicity LD50 (dog): Intravenous 176 mg/kg.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Potassium Citrate.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Potassium Citrate.Experimental, Illicit
Aluminum hydroxidePotassium Citrate can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Potassium Citrate.Experimental, Illicit, Withdrawn
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Potassium Citrate.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Potassium Citrate.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Potassium Citrate.Illicit, Vet Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Potassium Citrate.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Potassium Citrate.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Potassium Citrate.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Potassium Citrate.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Potassium Citrate.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Potassium Citrate.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Potassium Citrate.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Potassium Citrate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Potassium Citrate.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Potassium Citrate.Illicit, Vet Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Potassium Citrate.Approved, Illicit, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Potassium Citrate.Approved, Illicit
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Potassium Citrate.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Potassium Citrate.Approved, Illicit
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Potassium Citrate.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Potassium Citrate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Potassium Citrate.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Potassium Citrate.Illicit
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Potassium Citrate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Potassium Citrate.Approved, Illicit
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Potassium Citrate.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Potassium Citrate.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Potassium Citrate.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Potassium Citrate.Approved, Illicit
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Potassium Citrate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Potassium Citrate.Approved, Vet Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Potassium Citrate.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Potassium Citrate.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium Citrate.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Potassium Citrate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Potassium Citrate.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Monograph [Link]
  2. safety data sheet [Link]
External Links
ATC CodesA12BA02
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (81.6 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentBone Diseases / Metabolic Acidosis / Mineral Metabolism / Physical Capacity / Renal Transplant Patients1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentHypercalciuria / Renal Calculus1
3Unknown StatusPreventionNephrocalcinosis1
4RecruitingTreatmentRenal Stones / Urolithiasis1
4Unknown StatusTreatmentBone Diseases, Metabolic / Postmenopausal Osteoporosis (PMO)1
Not AvailableCompletedDiagnosticRenal Calculus1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
TabletOral
LiquidOral
TabletOral10 meq/1
TabletOral15 meq/1
TabletOral5 meq/1
Tablet, extended releaseOral1080 mg/1
Tablet, extended releaseOral5 meq/1
SolutionOral
Granule, for solutionOral
Tablet, extended releaseOral540 mg
Tablet, extended releaseOral10 meq/1
Tablet, extended releaseOral1080 mg
Tablet, extended releaseOral15 meq/1
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility39.4 mg/mLALOGPS
logP-0.7ALOGPS
logP-1.3ChemAxon
logS-0.89ALOGPS
pKa (Strongest Acidic)3.05ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area140.62 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity68.14 m3·mol-1ChemAxon
Polarizability14.23 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassTricarboxylic acids and derivatives
Direct ParentTricarboxylic acids and derivatives
Alternative Parents
Substituents
  • Tricarboxylic acid or derivatives
  • Tertiary alcohol
  • Carboxylic acid salt
  • Organic alkali metal salt
  • Carboxylic acid
  • Organic oxygen compound
  • Organic oxide
  • Hydrocarbon derivative
  • Organic potassium salt
  • Organic salt
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors
Comments
comments powered by Disqus
Drug created on September 23, 2015 10:41 / Updated on March 08, 2017 14:11